High Grade Ependymoma

High-grade ependymoma is a fast-growing brain or spinal cord tumor that starts from ependymal cells, which line the fluid-filled spaces (ventricles) and central canal of the spinal cord. Today, doctors name ependymomas mainly by where they start (supratentorial/brain’s upper part, posterior fossa/back of brain, or spinal), and by molecular markers (for example ZFTA-fusion in supratentorial tumors; PFA/PFB groups in the posterior fossa; MYCN-amplified in the spine). These molecular features help predict behavior and guide treatment choices. Standard care is to remove as much tumor as safely possible (gross total resection), then give focused radiotherapy to the tumor bed. Chemotherapy has a limited, selective role; many drugs remain investigational or used at relapse. Outcomes depend on location, extent of removal, and biology. Close, long-term follow-up is needed. PMC+3Cancer.gov+3PMC+3

High-grade ependymoma is a fast-growing cancer that starts from ependymal cells. These cells line the fluid-filled spaces in the brain (ventricles) and the central canal of the spinal cord. “High-grade” means the tumor cells look very abnormal and divide quickly. In the current World Health Organization (WHO) system, high-grade ependymoma corresponds to CNS WHO grade 3. These tumors can block the normal flow of cerebrospinal fluid (CSF), raise pressure inside the head, and cause neurological problems. Modern care describes ependymomas by where they arise (supratentorial, posterior fossa, spinal cord) and by molecular features (specific genetic and epigenetic changes), because these predict behavior better than grade alone. Cancer.gov+1

Other names

• Anaplastic ependymoma (older term that roughly matches grade 3)

• Grade 3 ependymoma

• Malignant ependymoma

• CNS WHO grade 3 ependymoma
  (Clinicians now also say things like “posterior fossa ependymoma, PFA” or “supratentorial ZFTA-fusion ependymoma,” because these labels capture important biology.) PMC+1

---

Types

Doctors classify ependymomas by location and molecular profile. Any of these can show high-grade (grade 3) features, but some are naturally more aggressive.

1. Supratentorial ependymoma, ZFTA-fusion–positive
   Occurs in the top part of the brain. It is commonly driven by a ZFTA-RELA gene fusion and tends to behave aggressively. Oxford Academic+1

2. Supratentorial ependymoma, YAP1-fusion–positive
   Also in the top part of the brain; less common. Usually in children. Behavior varies. PMC

3. Posterior fossa ependymoma, group A (PFA)
   In the back/lower part of the brain, mostly in infants and young children. Poorer prognosis than PFB. Often shows loss of H3K27me3 on testing. PMC+1

4. Posterior fossa ependymoma, group B (PFB)
   Also in the back of the brain, more often in older children/adolescents. Generally better prognosis than PFA. PMC

5. Spinal ependymoma (conventional)
   Arises within the spinal cord. Can be grade 2 or grade 3 based on microscopic features like high cellularity and increased mitoses. E-Neurospine

6. Spinal ependymoma, MYCN-amplified
   A recently recognized, particularly aggressive spinal subtype with a distinct molecular signature and a tendency to spread. PMC+1

Takeaway: Location + molecular features guide prognosis and treatment more precisely than grade alone. Cancer.gov

---

Causes

Most people want to know “Why did this happen?” For ependymoma, there is no single known lifestyle cause. Research points to a combination of rare inherited risks and changes within the tumor cells themselves. Below are 20 evidence-based factors and mechanisms, grouped in plain language. (Some are risk factors; some are tumor-cell drivers.)

1. Unknown cause in most cases
   For many patients, we can’t identify a clear trigger. This is common in brain and spinal cord tumors. Mayo Clinic

2. Rare inherited syndromes
   A small fraction of cases occur in people with tumor-predisposition conditions. Overall, germline mutations explain only a few percent of childhood ependymomas. Medscape

3. Neurofibromatosis type 2 (NF2)
   NF2 is a well-known risk for spinal ependymoma and other CNS tumors. PMC+1

4. Neurofibromatosis type 1 (NF1)
   Population data suggest NF1 can be associated with childhood ependymoma, though this is uncommon. Medscape

5. Prior ionizing radiation to the brain/spine
   Therapeutic radiation in childhood is a validated environmental risk for later primary CNS tumors (not specific to ependymoma but relevant). PubMed+1

6. ZFTA-RELA fusion (tumor-cell driver)
   This gene fusion is a dominant driver in many supratentorial tumors and can drive tumor formation by altering NF-κB signaling. AACR Journals+1

7. YAP1 fusions (tumor-cell driver)
   Another driver in supratentorial ependymomas, especially in children. PMC

8. MYCN amplification in spinal tumors
   Marks a high-risk spinal subtype with aggressive behavior and early spread. PMC

9. Loss of H3K27me3 / EZHIP overexpression
   A hallmark of PFA tumors that links to more aggressive disease biology. PMC

10. Occasional H3K27M mutations in PFA
    Less common, but mechanistically tied to the same epigenetic pathway. BioMed Central

11. Chromosome 1q gain in PFA
    A genomic change often linked to worse outcomes in posterior fossa group A disease. ScienceDirect

12. Younger age for PFA tumors
    PFA tends to occur in infants/young children; age distribution reflects underlying biology rather than behavior choices. Frontiers

13. Male sex (slight predominance overall)
    Ependymoma occurs more often in males than females in population datasets. Cancer.gov

14. Race/ethnicity patterns
    Higher overall occurrence in non-Hispanic White populations has been observed in US data. Cancer.gov

15. Neural stem/progenitor origin in cortex
    Experimental work shows ZFTA fusions can transform susceptible neural progenitors in the cortex, supporting a developmental origin. AACR Journals

16. Local microenvironment in posterior fossa
    Distinct epigenetic programs in the posterior fossa (e.g., PFA epigenetics) shape tumor behavior. PMC

17. Epigenetic dysregulation
    Global changes in chromatin marks (like H3K27me3 loss) are central to PFA biology. PMC

18. Molecular heterogeneity within subgroups
    Even within PFA or ZFTA-fusion tumors, additional molecular differences influence outcome. SpringerLink

19. Not linked to common lifestyle factors
    There is no consistent evidence connecting diet, phones, or routine environmental exposures to ependymoma risk. (Reviews of CNS tumor risks emphasize genetics and ionizing radiation.) SpringerLink

20. Most cases are sporadic
    For the majority, there is no family history and no identified trigger; the tumor arises from somatic changes in cells. Mayo Clinic

---

Symptoms

Symptoms depend on where the tumor grows and whether CSF flow is blocked. Here are plain-language descriptions:

1. Headache — often worse in the morning or with straining, from raised pressure in the head. UCSF Brain Tumor Center

2. Nausea and vomiting — commonly accompany increased intracranial pressure. UCSF Brain Tumor Center

3. Dizziness or balance problems — especially with posterior fossa tumors that affect the cerebellum. Cancer.gov

4. Walking unsteadily (ataxia) — trouble with coordination due to cerebellar involvement. PMC

5. Blurred or double vision — pressure on brain pathways for vision, or raised intracranial pressure. Mayo Clinic

6. Seizures — more likely when tumors are in the supratentorial (upper) brain. Cancer.gov

7. Neck pain or stiffness — can reflect posterior fossa involvement or spinal disease. Cancer.gov

8. Back pain — a key sign for spinal ependymoma. Barrow Neurological Institute

9. Numbness or tingling — spinal or brain pathway irritation. Weill Cornell Neurosurgery

10. Weakness in arms or legs — involvement of motor pathways. Barrow Neurological Institute

11. Trouble walking — from weakness, sensory loss, or balance problems. Weill Cornell Neurosurgery

12. Bowel or bladder problems — possible with spinal cord compression. Cancer.gov

13. Irritability or behavior change — sometimes seen with increased pressure or frontal lobe involvement. Yale Medicine

14. Hydrocephalus symptoms in infants/children — enlarged head size, downward gaze (“sunset eyes”), vomiting. Cancer.gov

15. Visual swelling of the optic nerve (papilledema) — seen by eye exam when pressure is high. NCBI

---

Diagnostic tests

Diagnosis combines clinical exam, MRI, and tissue testing. Doctors also look for spread through the CSF (drop metastases). Here’s what each test adds.

A) Physical examination (neurologic bedside assessment)

1. General neurological exam
   Checks mental status, cranial nerves, strength, sensation, coordination, reflexes, and gait. Abnormal findings point to which part of the nervous system is affected and whether urgent imaging is needed. NCBI

2. Cranial nerve exam
   Looks for facial weakness, swallowing trouble, double vision, or hearing issues. This helps localize a posterior fossa tumor that presses brainstem pathways. University of Rochester Medical Center

3. Motor strength testing
   Manual resistance testing detects subtle weakness in specific muscle groups and helps follow changes over time. NCBI

4. Coordination testing (finger-to-nose, heel-to-shin)
   Uncovers cerebellar problems common in posterior fossa tumors. Stanford Medicine

5. Gait and station assessment
   Watching how a person stands and walks can reveal ataxia or weakness, guiding urgent imaging. University of Rochester Medical Center

6. Funduscopic (eye) exam for papilledema
   Swelling of the optic disc suggests raised intracranial pressure from CSF blockage. It’s a red flag to image the brain. NCBI

B) Manual/bedside tests that add detail

7. Romberg test (balance with eyes closed)
   Helps distinguish cerebellar from sensory ataxia; instability supports a neurologic cause for unsteadiness. NCBI

8. Tandem gait (heel-to-toe walking)
   A simple way to screen for subtle cerebellar or vestibular imbalance that may occur with posterior fossa disease. Neurology at Washington University

9. Reflex testing and pathologic signs (e.g., Babinski)
   Upper motor neuron signs point toward central nervous system involvement and support the need for MRI. AMBOSS

10. Sensory mapping (light touch, pin, vibration)
    Finds sensory level in spinal cord disease or focal deficits from brain lesions. NCBI

C) Laboratory & pathological tests (the definitive diagnosis)

11. Surgical tumor tissue exam (histopathology)
    Under the microscope, grade-3 ependymomas show high cellularity, brisk mitoses, microvascular proliferation; perivascular pseudorosettes are characteristic. This confirms the tumor type and grade. E-Neurospine

12. Immunohistochemistry: GFAP and EMA
    Ependymomas often express GFAP and show dot-like or ring-like EMA staining, reflecting tiny microlumens—useful clues to the diagnosis. PMC+1

13. Ki-67 (MIB-1) proliferation index
    A higher Ki-67 labeling index correlates with higher grade and worse outcomes; it helps stratify risk. PMC+1

14. H3K27me3 immunostaining
    Loss of H3K27me3 supports PFA in posterior fossa tumors and signals a more aggressive course. PMC

15. Fusion testing (ZFTA, YAP1) and other molecular assays
    FISH/RT-PCR/NGS can detect ZFTA-RELA or YAP1 fusions in supratentorial tumors; this clarifies the subtype and biology. PMC+1

16. DNA methylation profiling
    A powerful tool now recommended in CNS tumor diagnostics to classify ependymoma when routine histology is ambiguous. PMC+1

17. CSF cytology
    Looks for tumor cells in spinal fluid, because ependymoma can spread (“drop metastases”). Usually performed after imaging and when safe. Frontiers

D) Electrodiagnostic tests (used in selected situations)

18. EEG (electroencephalogram)
    If seizures or confusion occur, EEG helps detect electrical seizure activity and guides anti-seizure treatment. Medscape

19. Evoked potentials (BAER/VEP/SSEP/MEP)
    Brainstem auditory evoked responses (BAER) and visual evoked potentials (VEP) can assess pathway function and are sometimes used during surgery to monitor and protect critical tracts. Somatosensory/motor evoked potentials may be used in spine surgery. PMC+1

E) Imaging tests (the backbone of diagnosis and staging)

20. MRI of brain and entire spine with contrast
    This is the key test to detect the tumor, assess hydrocephalus, and check for spread along the neuraxis. CT is less sensitive but may show calcification. MRI guides surgery and follow-up. Cancer.gov+1

Non-pharmacological treatments (therapies & others)

(Each item: description → purpose → basic mechanism)

1. Maximal safe microsurgical resection
   Neurosurgeons aim to remove the entire tumor while protecting brainstem, cranial nerves, and vital tracts. Tools like neuronavigation, neuro-monitoring, and intra-op imaging help surgeons see tumor edges and avoid injury. The purpose is durable local control and better survival; mechanism is mechanical removal of tumor bulk, which reduces residual cells that can regrow and lowers pressure in the brain. Repeat “second-look” surgery may be considered if a small remnant is left after the first operation. Cancer.gov+2The Journal of NeuroScience+2

2. Conformal external-beam radiotherapy (EBRT)
   After healing from surgery, highly shaped radiation targets the tumor bed with a small safety margin. Purpose: kill microscopic cells left behind to prevent local recurrence. Mechanism: DNA damage in cancer cells > normal tissue through precise dose planning. Typical total dose for older children and adults is around 59.4 Gy in 1.8 Gy fractions; lower doses are used in very young children. PMC+2PMC+2

3. Proton-beam therapy
   Protons can reduce dose to surrounding healthy tissue compared with photons, which is important near brainstem and cochlea. Purpose: maintain tumor control while lowering long-term side effects. Mechanism: Bragg peak lets energy stop at a set depth, sparing exit dose. Red Journal+1

4. Stereotactic radiosurgery or re-irradiation (salvage)
   When tumors recur locally or at small sites, focused dose (SRS) or carefully planned re-irradiation can control disease. Purpose: non-invasive local control when further open surgery is risky. Mechanism: ablative high-dose radiation to small targets. Cancer.gov

5. Hydrocephalus management (EVD, ETV, or VP shunt)
   Tumors in the posterior fossa can block cerebrospinal fluid (CSF) flow and cause pressure. Purpose: relieve pressure and protect the brain. Mechanism: temporary external drainage (EVD), endoscopic third ventriculostomy (ETV) to bypass the block, or ventriculo-peritoneal (VP) shunt for long-term diversion. PMC+1

6. Neuro-rehabilitation (physical therapy)
   After brain or spinal surgery, balance, strength, and walking can be affected. Purpose: restore mobility and reduce falls. Mechanism: task-specific, progressive exercises to retrain neural pathways and muscles. NCCN

7. Occupational therapy & activities of daily living (ADLs)
   OT helps with self-care, school/work tasks, and adapting the home or tools. Purpose: independence and safety. Mechanism: graded practice, adaptive devices, and energy conservation. NCCN

8. Speech, language, and swallowing therapy
   Posterior fossa disease can cause dysarthria, dysphagia, or language issues. Purpose: safer swallowing and clearer speech. Mechanism: targeted muscle exercises and compensatory strategies. NCCN

9. Neuropsychology & cognitive rehabilitation
   Attention, processing speed, and memory can change after treatment. Purpose: keep learning and work performance strong. Mechanism: assessment plus training, external memory aids, school/office accommodations. NCCN

10. Psychosocial counseling and caregiver support
    Anxiety and mood symptoms are common. Purpose: resilience and quality of life. Mechanism: counseling, support groups, and skills training to manage stress. NCCN

11. Return-to-school/work planning
    Coordinated plans with teachers/employers. Purpose: smooth reintegration with needed accommodations. Mechanism: 504/IEP (where applicable), flexible schedules, rest breaks. NCCN

12. Nutrition counseling
    Many patients lose weight or appetite. Purpose: maintain strength, prevent malnutrition. Mechanism: individualized plans targeting ~25–30 kcal/kg/day and ≥1.0–1.5 g protein/kg/day when feasible; avoid high-dose micronutrient megadoses. ESPEN+1

13. Exercise therapy
    Supervised aerobic + resistance work improves fatigue and function during/after treatment. Purpose: energy and physical capacity. Mechanism: improves cardiorespiratory fitness and muscle mass; aim for regular, moderate activity adjusted to symptoms. ASCO Publications

14. Fertility and endocrine evaluation
    Radiation near hypothalamus/pituitary or spine may affect hormones; counsel before therapy. Purpose: preserve fertility and manage hormone issues. Mechanism: baseline labs, sperm/egg preservation discussion, and long-term endocrine follow-up. Cancer.gov

15. Hearing and vestibular rehabilitation
    Therapy to address balance or hearing changes after posterior fossa irradiation. Purpose: safety and communication. Mechanism: vestibular therapy, hearing aids/cochlear rehab as needed. PMC

16. Vision and ocular motility therapy
    For double vision or tracking problems. Purpose: safer reading/mobility. Mechanism: orthoptic exercises, prisms, referral to low-vision services. Cancer.gov

17. Pain management using non-drug methods
    CBT, relaxation, mindfulness, and pacing reduce headache and neuropathic pain impact. Purpose: symptom relief with fewer medicines. Mechanism: cognitive and behavioral techniques. ESMO

18. Palliative care integration
    Palliative teams improve symptom control and decision support at any stage. Purpose: quality of life. Mechanism: multidisciplinary support for pain, mood, sleep, and goals of care. ESMO

19. Sleep hygiene interventions
    Regular routines, light exposure, and screen limits can help insomnia and fatigue. Purpose: better sleep and daytime energy. Mechanism: circadian and behavioral strategies. NCCN

20. Vaccinations and infection-prevention coaching
    Treatment can weaken immunity; routine vaccines and hygiene reduce infections (timing per oncology team). Purpose: avoid preventable illness. Mechanism: guideline-based scheduling and counseling. Cancer.gov

---

Drug treatments

(Note: chemotherapy has limited, selective benefit in ependymoma; doses below are typical examples—your oncology team individualizes all dosing. I list antitumor drugs first, then common supportive medicines.)

1. Temozolomide (alkylating agent)
   Often used at relapse; activity is variable in ependymoma. Typical adult cycle: 150–200 mg/m² orally once daily on days 1–5 of a 28-day cycle. Purpose: damage tumor DNA; Mechanism: methylates guanine (O6-MeG). Side effects: cytopenias, nausea, fatigue; consider PJP prophylaxis with prolonged use/steroids. Cancer.gov

2. Cisplatin (platinum) / Carboplatin (platinum)
   Sometimes used in pediatric protocols or salvage combinations. Dosing varies by protocol (e.g., cisplatin 75–100 mg/m² q3–4 weeks). Purpose: crosslink DNA. Side effects: nausea, kidney injury, hearing loss (cisplatin), marrow suppression. Cancer.gov

3. Vincristine (vinca alkaloid)
   Common in pediatric combinations. Example: 1.4 mg/m² IV weekly (capped). Purpose: disrupt microtubules; Side effects: neuropathy, constipation. Cancer.gov

4. Etoposide (topoisomerase II inhibitor)
   Used in relapse regimens; dosing varies (e.g., 100 mg/m² IV days 1–3 q3–4 weeks or oral schedules). Side effects: neutropenia, mucositis. Cancer.gov

5. Cyclophosphamide / Ifosfamide (alkylators)
   Occasionally included in multi-agent regimens for recurrent disease. Purpose: DNA crosslinking. Side effects: cytopenias, hemorrhagic cystitis (use mesna with ifosfamide). Cancer.gov

6. Methotrexate (antimetabolite; high-dose in infants/selected settings)
   Sometimes used when radiotherapy is deferred in very young children. Requires leucovorin rescue and careful monitoring. Side effects: mucositis, renal/hepatic toxicity. Cancer.gov

7. Topotecan / Irinotecan (topoisomerase I inhibitors)
   Used in some salvage protocols; diarrhea (irinotecan) and myelosuppression are common. Purpose: inhibit DNA repair during replication. Cancer.gov

8. Bevacizumab (anti-VEGF monoclonal antibody)
   Tested in recurrent ependymoma sometimes with lapatinib; responses are inconsistent. Typical: 10 mg/kg IV q2 weeks in trials. Risks: hypertension, bleeding, wound-healing issues.

9. Lapatinib (EGFR/HER2 TKI; investigational in ependymoma)
   Studied in children with ependymoma; given orally daily; disease control modest in small studies. Side effects: rash, diarrhea.

10. Panobinostat (HDAC inhibitor; investigational/locoregional)
    Soluble panobinostat (MTX110) via intraventricular routes has shown early safety in pediatric brain tumors, including ependymoma. Purpose: epigenetic modulation; Side effects depend on route/dose. The Journal of NeuroScience

11. PD-1 inhibitors (Nivolumab/Pembrolizumab; investigational)
    Tried across rare CNS tumors including ependymoma; benefit remains unproven. Dosing per trials (e.g., nivolumab 240–480 mg IV). Immune-related adverse events can affect skin, gut, lungs, and endocrine organs. MD Anderson Cancer Center

12. Everolimus (mTOR inhibitor; investigational)
    Occasionally used off-label in refractory cases; aims to slow tumor cell growth via mTOR blockade. Side effects: mouth sores, hyperlipidemia. Cancer.gov

13. Dexamethasone (glucocorticoid; supportive)
    Used short-term to reduce edema and headaches around surgery or radiation. Dose is tapered to the lowest effective level. Side effects: high blood sugar, mood change, infection risk. Cancer.gov

14. Levetiracetam (anti-seizure; supportive)
    Given if seizures occur or peri-operatively in selected cases. Typical: 500–1,000 mg twice daily titrated to effect. Side effects: fatigue, irritability. Cancer.gov

15. Ondansetron (5-HT3 blocker; antiemetic)
    Prevents chemotherapy- and radiation-induced nausea. Example: 8 mg PO/IV before emetogenic therapy; repeat per guideline risk level. Side effects: constipation, QT prolongation. ASCO Publications+1

16. NK1 antagonists (e.g., aprepitant/fosaprepitant; antiemetic)
    Added for moderate/high emetogenic regimens with dexamethasone and a 5-HT3 blocker. Side effects: hiccups, fatigue, drug interactions. ASCO Publications

17. Proton-pump inhibitor (e.g., pantoprazole; supportive)
    Protects stomach during steroid or multi-drug therapy as indicated. Side effects: headache, low magnesium with long use. Cancer.gov

18. Trimethoprim-sulfamethoxazole (PJP prophylaxis when appropriate)
    Used if prolonged steroids or temozolomide-based regimens raise Pneumocystis risk. Typical: 1 double-strength tablet 3 times weekly. Side effects: rash, cytopenias. Cancer.gov

19. G-CSF (pegfilgrastim/filgrastim; supportive)
    Speeds neutrophil recovery after myelosuppressive chemo to lower infection risk. Side effects: bone pain, rare splenic issues. Cancer.gov

20. Acetaminophen (analgesic/antipyretic; supportive)
    Relieves headache and fever; avoid exceeding daily max or combining with hepatotoxic drugs. Cancer.gov

---

Dietary molecular supplements

Important: major societies advise meeting RDAs and avoiding high-dose megavitamins unless you have a documented deficiency. Always clear supplements with your oncology team for interactions. ESPEN

1. Protein supplementation (whey/plant blends)
   Helps meet ≥1.0–1.5 g/kg/day protein targets during therapy when appetite is low; supports muscle mass and wound healing. Mechanism: provides essential amino acids (leucine-rich) to stimulate muscle protein synthesis. Dose: individualized to close the daily gap. ESMO Open

2. Omega-3 fatty acids (EPA/DHA)
   May support calorie intake and help counter cancer-related weight loss in some patients; mechanism: anti-inflammatory effects and possible appetite support. Typical supplemental range: 1–2 g/day combined EPA+DHA if approved by your team. PMC

3. Vitamin D (if deficient)
   Correcting deficiency supports bone health and immunity during long treatments or steroids. Dose: based on blood levels; avoid megadoses without testing. ESPEN

4. Multivitamin at RDA levels
   Covers baseline micronutrient needs when intake is inconsistent. Avoid high-dose antioxidants that may interfere with therapy. ESPEN

5. Oral nutrition supplements (complete formulas)
   Energy-dense shakes help meet 25–30 kcal/kg/day targets during low appetite phases. Dose: 1–3 servings/day as needed. ESPEN

6. Soluble fiber (e.g., psyllium)
   Supports bowel regularity; helpful with opioid-related constipation or post-op changes. Dose: start low and increase with fluids. American Cancer Society

7. Probiotics (select strains, if appropriate)
   May help antibiotic-associated diarrhea; discuss safety if neutropenic. Dose/strain per clinician guidance. ESPEN

8. Electrolyte solutions
   Support hydration during nausea/diarrhea; mechanism: replace sodium/potassium/glucose for absorption. Use as directed. American Cancer Society

9. Iodized salt (small amounts)
   If intake is very restricted, iodized salt helps maintain iodine for thyroid health—important if cranial irradiation risks endocrine effects. Use sparingly as medically advised. Cancer.gov

10. Calcium (if intake is low)
    Supports bone health with steroid use or reduced mobility; dose per dietitian and total dietary intake. ESPEN

---

Drugs for “immunity-support / regenerative / stem-cell

In ependymoma, “immune-boosters” are not standard anti-cancer therapy. Below are contexts where immune-modulating or regenerative strategies may appear; most are supportive or investigational.

1. Seasonal vaccines (e.g., influenza) and routine immunizations
   Goal: prevent infections during/after therapy. Timing is coordinated with oncology to maximize safety and efficacy. Mechanism: adaptive immune priming. Cancer.gov

2. G-CSF / GM-CSF
   Promote white-cell recovery after cytotoxic chemotherapy to lower febrile-neutropenia risk. Mechanism: stimulates myeloid progenitors. (Supportive, not anti-tumor.) Cancer.gov

3. Immune checkpoint inhibitors (e.g., nivolumab; investigational in ependymoma)
   Trials across rare CNS tumors are ongoing; benefit in ependymoma is unproven so far. Mechanism: restores T-cell activity against tumor antigens. MD Anderson Cancer Center

4. Autologous hematopoietic stem-cell rescue after high-dose chemotherapy (rare/investigational)
   Used mainly in selected pediatric settings or trials; evidence is limited and risks are significant. Mechanism: allows temporary dose-intense chemo, then restores marrow with your own stem cells. Premera Blue Cross+1

5. Panobinostat (HDAC inhibitor) via intraventricular infusion (investigational)
   Early studies suggest feasibility/safety for fourth-ventricle delivery; not standard. Mechanism: epigenetic modulation to slow tumor growth. The Journal of NeuroScience

6. Clinical-trial vaccines/targeted cellular approaches
   Occasional pilot studies attempt tumor-specific immune responses; this is highly experimental. Mechanism: present tumor antigens to stimulate targeted immunity. Cancer.gov

---

Surgeries

1. Primary tumor resection (craniotomy or spinal laminectomy)
   Procedure: microsurgical removal using neuronavigation and monitoring. Why: the extent of resection is the most important modifiable prognostic factor—more complete removal improves local control and survival. The Journal of NeuroScience

2. Second-look (re-resection)
   Procedure: planned re-operation to remove small residual disease after the first surgery. Why: to achieve gross total resection when safe after swelling settles. ScienceDirect

3. Endoscopic third ventriculostomy (ETV) / ventriculoperitoneal (VP) shunt
   Procedure: create an internal CSF bypass (ETV) or place a shunt to drain CSF. Why: treat hydrocephalus caused by CSF blockage from posterior fossa tumors. PMC

4. Spinal stabilization (selected spinal cases)
   Procedure: instrumented fusion if wide laminectomy causes instability. Why: protect the spinal cord and maintain alignment. Cancer.gov

5. Stereotactic biopsy (rarely, if diagnosis uncertain or unresectable)
   Procedure: needle sampling for pathology and molecular tests. Why: confirm diagnosis to plan therapy when resection is unsafe. Cancer.gov

---

Preventions

1. Adhere to follow-up MRI schedules to catch recurrence early. Cancer.gov

2. Report new headaches, vomiting, gait, or vision changes immediately. Cancer.gov

3. Protect hearing during platinum chemo and posterior fossa radiation (baseline and follow-up audiology). PMC

4. Infection prevention: hand hygiene, vaccines per plan, prompt fever reporting. Cancer.gov

5. Nutrition and weight maintenance: target 25–30 kcal/kg/day and adequate protein. ESPEN

6. Regular physical activity within safe limits to reduce fatigue and improve function. ASCO Publications

7. Falls prevention with PT/OT and home safety checks. NCCN

8. Endocrine and fertility monitoring after cranial/spinal radiation. Cancer.gov

9. Hearing/vision checks to manage late effects early. PMC

10. Avoid high-dose unproven supplements that may interact with therapy; meet RDAs unless deficient. ESPEN

---

When to see a doctor urgently

See your team now for: severe or sudden headache, repeated vomiting, new weakness, seizures, sudden balance problems, confusion, fever during chemotherapy, wound redness or drainage, or any rapid change in vision, hearing, or swallowing. These can signal tumor pressure, hydrocephalus, infection, treatment toxicity, or bleeding that need prompt care. Cancer.gov

---

What to eat & what to avoid

Eat more of:

1. Lean proteins (fish, poultry, legumes) to help reach ≥1.0–1.5 g/kg/day protein targets. ESMO Open

2. Whole grains and starchy vegetables for energy when appetite is low. ESPEN

3. Colorful fruits and vegetables daily for vitamins/minerals at RDA levels. American Cancer Society

4. Healthy fats (olive oil, nuts, seeds; omega-3-rich fish). PMC

5. Adequate fluids/electrolytes, especially during nausea or diarrhea. American Cancer Society

Limit/avoid:

1. Alcohol (can worsen balance and interact with meds). UNC Lineberger
2. Highly processed, high-sugar drinks and snacks when trying to maintain steady energy and weight. The ASCO Post
3. High-dose antioxidant or herbal megadoses without oncology approval. ESPEN
4. Raw/undercooked meats and unpasteurized foods during neutropenia (infection risk). Cancer.gov
5. Excess caffeine late in the day if sleep is a problem. NCCN

---

FAQs

1. Is high-grade ependymoma the same as “anaplastic ependymoma”?
   Historically, yes. Modern WHO naming focuses more on location + molecular group (e.g., PFA/PFB, ZFTA-fusion). Cancer.gov

2. What treatment helps most?
   Maximal safe surgery plus focused radiotherapy to the tumor bed gives the best chance of local control. Cancer.gov+1

3. Is chemotherapy always used?
   No. Chemo has a limited role; it’s used in selected protocols or at relapse, and many drugs are investigational. Cancer.gov

4. What dose of radiation is typical?
   Many protocols use ~59.4 Gy in 1.8 Gy fractions for older children/adults, with adjustments for very young children. PMC+1

5. Are protons better than photons?
   Both control tumors; protons can reduce dose to healthy tissue, which may cut long-term side effects—use depends on availability and anatomy. Red Journal

6. What if the tumor comes back?
   Options include re-resection, stereotactic radiosurgery, or carefully planned re-irradiation; clinical trials are encouraged. Cancer.gov

7. Will my child need a shunt?
   Some do. Hydrocephalus may need ETV or a VP shunt depending on response after tumor removal. PMC

8. How often are MRIs done?
   Regular MRIs are scheduled after treatment to monitor for recurrence; timing is set by your team and guidelines. Cancer.gov

9. Can diet cure ependymoma?
   No. Diet supports strength and recovery; stick to RDAs and avoid megadoses unless deficient. ESPEN

10. How much protein should I aim for during treatment?
    Guidelines often target ≥1.0–1.5 g/kg/day if feasible, individualized by a dietitian. ESMO Open

11. What exercise is safe?
    Guidelines support regular, moderate activity tailored to symptoms; PT can design a plan. ASCO Publications

12. Are immunotherapies a standard option?
    Not yet for ependymoma; they’re under study in clinical trials. MD Anderson Cancer Center

13. Do molecular results change care?
    Yes—classification now includes ZFTA/YAP1 fusions (supratentorial) and PFA/PFB (posterior fossa), guiding prognosis and trials. Cancer.gov

14. Can a second surgery help?
    Yes, “second-look” surgery can increase the chance of complete removal if safe. ScienceDirect

15. Where can I read clinician-level summaries updated this year?
    The NCI PDQ pages are peer-reviewed and updated regularly. NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.